The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...

Novo Nordisk NVO shares have lost 15.2% so far ... NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. The company has a strong presence ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...